A trial of KK2845 for certain blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer called acute myeloid leukemia (AML) or another blood cancer that has come back or not responded to treatment.
- You are at least 18 years old.
- You are in generally good health for your age, able to care for yourself (ECOG score 0-2).
- Your kidney and liver function are within acceptable limits.
- You have not had a stem cell transplant from a donor, or if you did, it was at least 6 months ago with no ongoing graft-versus-host disease.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (RJK-RT2831) for people with AML that has not responded to standard treatments. The drug targets two markers on leukemia cells (CD33 and CD123). The study is early-stage, aiming to find the right dose and check safety.
This is an early-stage study testing a new drug called KK2430 in people with blood cancers (like leukemia or lymphoma). The goal is to find the right dose and see if it helps shrink tumors.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new Relapsed or Refractory AML and Other Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.